Veru to present at obesityweek: meta-analysis of 4 previous randomized clinical trials that support the potential of enobosarm to optimize weight loss

Miami, fl, oct. 21, 2024 (globe newswire) -- veru inc. (nasdaq: veru), a late clinical stage biopharmaceutical company focused on developing innovative medicines for preserving muscle for high quality weight loss, oncology, and viral induced acute respiratory distress syndrome, today announced that the company will present at obesityweek, taking place november 3-6, 2024, in san antonio, texas.
VERU Ratings Summary
VERU Quant Ranking